XHKG1167
Market cap129mUSD
Jan 02, Last price
1.28HKD
1D
0.79%
1Q
-43.36%
IPO
-91.44%
Name
Jacobio Pharmaceuticals Group Co Ltd
Chart & Performance
P/E
—
P/S
14.93
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.34%
Rev. gr., 5y
%
Revenues
64m
-33.66%
Net income
-359m
L-4.21%
CFO
-364m
L+24.55%
Earnings
Mar 26, 2025
Profile
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 63,520 -33.66% | 95,746 -37.34% | ||||
Cost of revenue | 479,252 | 571,310 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (415,732) | (475,564) | ||||
NOPBT Margin | ||||||
Operating Taxes | 3,022 | |||||
Tax Rate | ||||||
NOPAT | (415,732) | (478,586) | ||||
Net income | (359,119) -4.21% | (374,883) 28.26% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 133,455 | |||||
BB yield | -4.77% | |||||
| Debt | ||||||
Debt current | 87,945 | 13,131 | ||||
Long-term debt | 258,267 | 282,457 | ||||
Deferred revenue | 1,609 | |||||
Other long-term liabilities | 60,011 | 1,609 | ||||
Net debt | (819,816) | (1,013,431) | ||||
| Cash flow | ||||||
Cash from operating activities | (364,199) | (292,418) | ||||
CAPEX | (37,829) | (16,506) | ||||
Cash from investing activities | (48,001) | (686,322) | ||||
Cash from financing activities | 246,278 | (9,854) | ||||
FCF | (430,107) | (605,434) | ||||
| Balance | ||||||
Cash | 1,147,847 | 1,283,598 | ||||
Long term investments | 18,181 | 25,421 | ||||
Excess cash | 1,162,852 | 1,304,232 | ||||
Stockholders' equity | (3,193,276) | 1,282,524 | ||||
Invested Capital | 4,536,572 | 148,659 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 772,842 | 751,876 | ||||
Price | 3.62 -30.78% | 5.23 -59.14% | ||||
Market cap | 2,797,688 -28.85% | 3,932,311 -58.89% | ||||
EV | 1,977,872 | 2,918,880 | ||||
EBITDA | (390,652) | (461,769) | ||||
EV/EBITDA | ||||||
Interest | 8,312 | 2,270 | ||||
Interest/NOPBT | ||||||